BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17968881)

  • 21. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
    Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
    Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
    Rodriguez FJ; Scheithauer BW; Jenkins R; Burger PC; Rudzinskiy P; Vlodavsky E; Schooley A; Landolfi J
    Am J Surg Pathol; 2007 Mar; 31(3):351-62. PubMed ID: 17325476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
    Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
    Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
    Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
    Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
    Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas.
    Kitange G; Misra A; Law M; Passe S; Kollmeyer TM; Maurer M; Ballman K; Feuerstein BG; Jenkins RB
    Genes Chromosomes Cancer; 2005 Jan; 42(1):68-77. PubMed ID: 15472895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging correlates of molecular signatures in oligodendrogliomas.
    Megyesi JF; Kachur E; Lee DH; Zlatescu MC; Betensky RA; Forsyth PA; Okada Y; Sasaki H; Mizoguchi M; Louis DN; Cairncross JG
    Clin Cancer Res; 2004 Jul; 10(13):4303-6. PubMed ID: 15240515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.
    Khayal IS; Vandenberg SR; Smith KJ; Cloyd CP; Chang SM; Cha S; Nelson SJ; McKnight TR
    Neuro Oncol; 2011 Nov; 13(11):1192-201. PubMed ID: 21865401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No preferential loss of paternal 19q alleles in oligodendroglial tumors.
    Hartmann C; Mueller W; Lass U; Stockhammer F; von Eckardstein K; Veelken J; Jeuken J; Wick W; von Deimling A
    Ann Neurol; 2003 Aug; 54(2):256-8. PubMed ID: 12891681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors.
    Scheie D; Andresen PA; Cvancarova M; Bø AS; Helseth E; Skullerud K; Beiske K
    Am J Surg Pathol; 2006 Jul; 30(7):828-37. PubMed ID: 16819324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
    Born PW; Broholm H; Laursen H
    Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
    Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
    Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; Kopitzki K; du Plessis DG; Prosser J; Vinjamuri S; Warnke PC
    Br J Cancer; 2006 Nov; 95(10):1424-31. PubMed ID: 17031404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component.
    Walker C; du Plessis DG; Fildes D; Haylock B; Husband D; Jenkinson MD; Joyce KA; Broome J; Kopitski K; Prosser J; Smith T; Vinjamuri S; Warnke PC
    Clin Cancer Res; 2004 Nov; 10(21):7182-91. PubMed ID: 15534091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.
    Scheie D; Meling TR; Cvancarova M; Skullerud K; Mørk S; Lote K; Eide TJ; Helseth E; Beiske K
    Neuro Oncol; 2011 Nov; 13(11):1225-33. PubMed ID: 21856683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
    Kim SH; Kim H; Kim TS
    Acta Neuropathol; 2005 Jul; 110(1):27-38. PubMed ID: 15920661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema.
    Oh J; Cha S; Aiken AH; Han ET; Crane JC; Stainsby JA; Wright GA; Dillon WP; Nelson SJ
    J Magn Reson Imaging; 2005 Jun; 21(6):701-8. PubMed ID: 15906339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
    Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ
    J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.
    Zeng QS; Li CF; Liu H; Zhen JH; Feng DC
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):151-8. PubMed ID: 17289287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.